VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Shares Shorted: Short Interest Down 34.1% in October

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) was the target of a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 2,472,435 shares, a decline of 34.1% from the September 30th total of 3,750,912 shares. Currently, 5.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,137,394 shares, the short-interest ratio is presently 2.2 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Monday, August 31st. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $0.95.

Institutional Investors Weigh In On VistaGen Therapeutics

Hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC boosted its position in VistaGen Therapeutics by 49.2% in the first quarter. ADAR1 Capital Management LLC now owns 751,141 shares of the company’s stock valued at $429,000 after buying an additional 247,566 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of VistaGen Therapeutics by 81.2% during the first quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock worth $166,000 after buying an additional 130,509 shares in the last quarter. AdvisorShares Investments LLC increased its holdings in shares of VistaGen Therapeutics by 10.8% during the first quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock worth $158,000 after buying an additional 26,922 shares in the last quarter. Finally, BlackRock Inc. bought a new position in shares of VistaGen Therapeutics in the 2nd quarter valued at $78,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

VistaGen Therapeutics Stock Up 0.3%

Shares of VTGN stock opened at $0.17 on Wednesday. VistaGen Therapeutics has a twelve month low of $0.17 and a twelve month high of $5.14. The company has a market cap of $7.46 million, a P/E ratio of -0.10 and a beta of 0.49. The business has a fifty day simple moving average of $0.23 and a 200 day simple moving average of $0.44.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.06. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%. The business had revenue of $1.48 million for the quarter, compared to analyst estimates of $0.50 million. As a group, equities research analysts anticipate that VistaGen Therapeutics will post -1.45 earnings per share for the current fiscal year.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines.

Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder.